Brussels, Belgium – Univercells S.A. (“Univercells”), Univercells Technologies (the “Company”), and Gamma Biosciences (“Gamma”) are pleased to announce that effective March 15, 2021, Mathias Garny has been appointed as the Chief Executive Officer of Univercells Technologies, a Univercells company and global provider of next-generation bioprocess technologies. The appointment of Mr. Garny will usher a new era for the Company with a focus on commercializing the company’s product portfolio and new technology developments to further expand market reach and success.
Already acting as General Manager, Mr. Garny has been responsible for overseeing the Company’s operations and leading the strategy development and implementation. Under his leadership, the Company introduced new products and expanded international operations.
Mr. Garny first joined Univercells in 2015 as Chief Financial Officer to define the financial strategy and spearhead fundraising activities. As the company grew, he transitioned to Chief Commercial Officer in 2017, playing a key role in Univercells’ development and commercialization efforts of the technology portfolio, including the scale-X™ single-use bioreactor range and the NevoLine™ biomanufacturing platform.
In February 2020, Gamma Biosciences (“Gamma”), a global life sciences company backed by the investment firm KKR, invested EUR 50mn to launch Univercells Technologies following its carve-out from Univercells and accelerate the industrialization and commercialization of its manufacturing technologies. “Mathias has demonstrated exceptional leadership as we’ve sought to aggressively grow the Univercells Technologies offer as part of the Gamma platform and across the industry. In this new role as CEO, he will further advance the company’s mission to make biologics and gene therapies more affordable through its next generation bioprocessing and manufacturing technologies,” commented Matt Gunnison, President of Gamma Biosciences.
Hugues Bultot, CEO of Univercells commented: “The Board and I are delighted to appoint Mathias as the new CEO. His background in business strategy, operations, business planning, and fundraising are key assets that will help to ensure the sustained growth of Univercells Technologies. I am confident that Mathias will bring Univercells Technologies into the next phase of growth and see his appointment as an example of the internal career progression available in our companies.”
Mathias Garny addressed his new role, adding: “Univercells Technologies is a fantastic success story with a deep Belgian anchorage. We are built on strong values and entrepreneurial spirit and have grown a diverse pool of driven, forward-focused talents. I am honored to be trusted with the task of taking the Company through the next stage of strategic development and growth.”
Download the Press Release
PRESS RELEASE
Mathias Garny appointed as CEO of Univercells Technologies
Univercells, Univercells Technologies, and Gamma Biosciences are pleased to announce Mathias Garny has been appointed as the Chief Executive Officer of Univercells Technologies
DownloadMathias Garny devient CEO d’Univercells Technologies
La nomination de M. Garny marque le début d’une nouvelle ère pour la société dans la commercialisation et nouveaux développements technologiques afin d’étendre la portée du marché et son succès.
Visit site
About Univercells
Univercells is a global life sciences company that makes biologics available to all. Leveraging our core strengths in scaling, production, and bioprocessing, we build businesses and find new ways to support access to medicines and promote sustainability. Through entrepreneurship and technology-driven affordability, we address the needs of the entire health value chain.
Univercells is headquartered in Gosselies (Belgium) and benefits from the support of regional and national investors, as well as international investors, such as the Bill & Melinda Gates Foundation, Global Health Investment Fund, among others active in the health and vaccine industry.
About Univercells Technologies
Univercells Technologies is a global provider of innovative biomanufacturing technologies to achieve cost-effective viral production from R&D to commercial scales. The company offers a comprehensive technology portfolio leveraging the strengths of process intensification and chaining as a direct answer to the growing demand of viral vectors and viral vaccines. Univercells Technologies is committed to helping customers increase performance with minimized footprint and costs today, while anticipating the needs of tomorrow.
Building upon years of expertise and capitalizing on technology vetted by world leaders, Univercells Technologies was incorporated in Belgium in 2020 following its carve-out from Univercells with the support of the Univercells Group and Gamma Biosciences.
About Gamma Biosciences
Gamma Biosciences is a life sciences tools platform created by KKR. Gamma’s mission is to build a leading player in next-generation bioprocessing for advanced therapies by acquiring high-potential businesses with outstanding technology and accelerating their growth. For more information about Gamma Biosciences, please visit www.gammabiosciences.com .